ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,141 to 3,160 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Transdisciplinary Approach vs Multidisciplinary Approach: Wandering52 of 648

116 of 1,653

1.0 points

-1.3 to 3.6

2,301NCT03442322

Optimizing Care for Patients With Dementia

Folic Acid 4 mg vs Placebo: Severe Preeclampsia24 of 1,144

16 of 1,156

0.7 points

-0.4 to 1.8

2,300NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Folic Acid 4 mg vs Placebo: HELLP (Hemolysis, Elevated Liver Enzyme Levels & Low Platelet Count)6 of 1,144

5 of 1,156

0.1 points

-0.6 to 0.8

2,300NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

GBC+PIPT vs Guideline Based Care: Number of Patients Prescribed Opioids300 of 1,207

270 of 1,093

0.2 points

-3.4 to 3.7

2,300NCT02647658

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

GBC+PIPT vs Guideline Based Care: Number of Patients Referred to Physical Therapy658 of 1,207

335 of 1,093

23.9 points

19.9 to 27.7

2,300NCT02647658

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

GBC+PIPT vs Guideline Based Care: deaths from any cause8 of 1,207

12 of 1,093

-0.4 points

-1.3 to 0.4

2,300NCT02647658

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

Intervention vs Usual Care: 30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization)429 of 1,139

433 of 1,160

0.3 points

-3.6 to 4.3

2,299NCT02587936

Improving Chronic Disease Management With Pieces

Transdisciplinary Approach vs Multidisciplinary Approach: Falls274 of 644

700 of 1,652

0.2 points

-4.3 to 4.7

2,296NCT03442322

Optimizing Care for Patients With Dementia

Transdisciplinary Approach vs Multidisciplinary Approach: Physical Restraints Use4 of 644

91 of 1,652

-4.9 points

-6.2 to -3.5

2,296NCT03442322

Optimizing Care for Patients With Dementia

Washington vs Ohio: Not Working for Pay599 of 1,976

107 of 319

-3.2 points

-8.9 to 2.1

2,295NCT03932799

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

Washington vs Ohio: Global Improvement (GIC)1,413 of 1,976

222 of 319

1.9 points

-3.3 to 7.5

2,295NCT03932799

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

Washington vs Ohio: Problematic Opioid Use (TAPS)113 of 1,976

22 of 319

-1.2 points

-4.6 to 1.4

2,295NCT03932799

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

Washington vs Ohio: Depressive Symptoms (PHQ-4)322 of 1,976

64 of 319

-3.8 points

-8.8 to 0.6

2,295NCT03932799

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

Washington vs Ohio: Opioid Overdose/Adverse Effects2 of 1,976

0 of 319

0.1 points

-1.1 to 0.4

2,295NCT03932799

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

Washington vs Ohio: ≥30% Decrease in Pain Intensity/Interference (PEG-3)1,001 of 1,976

151 of 319

3.3 points

-2.6 to 9.2

2,295NCT03932799

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

Washington vs Ohio: Earning Less Than Before Injury819 of 1,976

129 of 319

1.0 points

-4.9 to 6.7

2,295NCT03932799

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

Washington vs Ohio: Anxious Symptoms (PHQ-4)487 of 1,976

79 of 319

-0.1 points

-5.5 to 4.7

2,295NCT03932799

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

Washington vs Ohio: On Time Loss (Not Working)209 of 1,976

43 of 319

-2.9 points

-7.3 to 0.7

2,295NCT03932799

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

1. Resolute - 12-13 Months vs 2. XIENCE V - 12-13 Months: serious adverse events435 of 1,140

432 of 1,152

0.7 points

-3.3 to 4.6

2,292NCT00617084

Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent

Transdisciplinary Approach vs Multidisciplinary Approach: Unintended Weight Loss132 of 640

395 of 1,651

-3.3 points

-6.9 to 0.6

2,291NCT03442322

Optimizing Care for Patients With Dementia

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=158"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=158

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03442322-51645470",
        "title": "Transdisciplinary Approach vs Multidisciplinary Approach: Wandering",
        "summary": "52 of 648 against 116 of 1653; risk difference 1.0 points, 95% interval -1.3 to 3.6; NCT03442322, Optimizing Care for Patients With Dementia",
        "record": "/library/comparisons/NCT03442322-51645470",
        "nct_id": "NCT03442322",
        "kind": "outcome",
        "participants": 2301,
        "risk_difference": {
          "value": 0.010071474983755685,
          "lower": -0.012757590940621802,
          "upper": 0.036144181391639496
        },
        "group_1": "52 of 648",
        "group_2": "116 of 1,653",
        "difference": "1.0 points",
        "interval": "-1.3 to 3.6",
        "trial_title": "Optimizing Care for Patients With Dementia"
      },
      {
        "id": "NCT01355159-4eafe09c",
        "title": "Folic Acid 4 mg vs Placebo: Severe Preeclampsia",
        "summary": "24 of 1144 against 16 of 1156; risk difference 0.7 points, 95% interval -0.4 to 1.8; NCT01355159, High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention",
        "record": "/library/comparisons/NCT01355159-4eafe09c",
        "nct_id": "NCT01355159",
        "kind": "outcome",
        "participants": 2300,
        "risk_difference": {
          "value": 0.00713819052919399,
          "lower": -0.0037915720109371106,
          "upper": 0.018499515166456544
        },
        "group_1": "24 of 1,144",
        "group_2": "16 of 1,156",
        "difference": "0.7 points",
        "interval": "-0.4 to 1.8",
        "trial_title": "High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=159",
  "request_id": "lGnQmFVpn-Xcry9I"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?